171 related articles for article (PubMed ID: 15524025)
1. [Pharmacoeconomics of vaccinations in chronic obstructive pulmonary disease].
Słominski JM; Kubiak A
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():83-5. PubMed ID: 15524025
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan.
Cai L; Uchiyama H; Yanagisawa S; Kamae I
Kobe J Med Sci; 2006; 52(3-4):97-109. PubMed ID: 16855372
[TBL] [Abstract][Full Text] [Related]
3. [Splenectomy and pneumococcal vaccination].
Postma MJ; Heijnen MA; de Vries R; Beutels P; Jager JC
Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1141-2; author reply 1142. PubMed ID: 12822527
[No Abstract] [Full Text] [Related]
4. [Pharmaco-economics of anti-influenza vaccinations].
Jahnz-Rózyk K
Pol Merkur Lekarski; 2003 Jun; 14(84):679-81. PubMed ID: 14524303
[TBL] [Abstract][Full Text] [Related]
5. Prevention of respiratory infections in adults. Influenza and pneumococcal vaccines.
Fiebach N; Beckett W
Arch Intern Med; 1994 Nov; 154(22):2545-57. PubMed ID: 7979851
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic vaccinations in chronic obstructive pulmonary disease: current status.
Varkey JB; Varkey AB; Varkey B
Curr Opin Pulm Med; 2009 Mar; 15(2):90-9. PubMed ID: 19532022
[TBL] [Abstract][Full Text] [Related]
7. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD.
Schembri S; Morant S; Winter JH; MacDonald TM
Thorax; 2009 Jul; 64(7):567-72. PubMed ID: 19321465
[TBL] [Abstract][Full Text] [Related]
8. [Prevention of pneumococcal infection by vaccination].
Bertz H
Fortschr Med Orig; 2001 Jul; 119 Suppl 2():71-5. PubMed ID: 15704359
[TBL] [Abstract][Full Text] [Related]
9. Compliance with influenza and pneumococcal vaccination among patients with chronic obstructive pulmonary disease consulting their medical practitioners in Catalonia, Spain.
Jiménez-García R; Ariñez-Fernandez MC; Hernández-Barrera V; Garcia-Carballo MM; de Miguel AG; Carrasco-Garrido P
J Infect; 2007 Jan; 54(1):65-74. PubMed ID: 17049991
[TBL] [Abstract][Full Text] [Related]
10. Comparison of outpatient visits and hospitalisations, in patients with chronic obstructive pulmonary disease, before and after influenza vaccination.
Menon B; Gurnani M; Aggarwal B
Int J Clin Pract; 2008 Apr; 62(4):593-8. PubMed ID: 18284444
[TBL] [Abstract][Full Text] [Related]
11. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over.
Kelly H; Attia J; Andrews R; Heller RF
Vaccine; 2004 Jun; 22(17-18):2192-8. PubMed ID: 15149776
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
13. [Introduction to asthma and chronic obstructive pulmonary disease pharmacoeconomics].
Jahnz-Rózyk K
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():5-6, 8. PubMed ID: 15524004
[TBL] [Abstract][Full Text] [Related]
14. [New ideas on the therapeutic effect of a combination of vaccines against pneumococcal, Haemophilus influenzae type b infection, and influenza in patients with chronic obstructive pulmonary disease].
Kostinov MP; Zhestkov AV; Protasov AD; Magarshak OO; Kostinova TA
Ter Arkh; 2015; 87(3):17-22. PubMed ID: 26027235
[TBL] [Abstract][Full Text] [Related]
15. Influenza and pneumococcal vaccination coverage among persons aged > or =65 years and persons aged 18-64 years with diabetes or asthma--United States, 2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2004 Nov; 53(43):1007-12. PubMed ID: 15525897
[TBL] [Abstract][Full Text] [Related]
16. The cost of chronic obstructive pulmonary disease and its effects on managed care.
Mapel D; Chen JC; George D; Halbert RJ
Manag Care Interface; 2004 Apr; 17(4):61-6. PubMed ID: 15108761
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacoeconomics aspects of long-acting beta-2 agonists in COPD patients].
Jahnz-Rózyk K; Targowski T
Pol Merkur Lekarski; 2010 Apr; 28(166):323-6. PubMed ID: 20491347
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
Postma MJ; Heijnen ML; Beutels P; Jager JC
Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of influenza vaccination and pneumococcal vaccination in elderly and high-risk patients seen in a university general medicine clinic.
Lai H; Aronow WS; Gutwein AH
Am J Ther; 2008; 15(6):528-30. PubMed ID: 19127136
[TBL] [Abstract][Full Text] [Related]
20. [Simultaneous vaccination against influenza and invasive pneumococcal disease in chronic dialysis patients].
Trmal J; Havlícková M; Bícová R; Bitterová Z; Kelerová J
Epidemiol Mikrobiol Imunol; 2005 Aug; 54(3):123-8. PubMed ID: 16173523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
